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Abstract
Background: Guidelines on cardiovascular disease (CVD) risk reassessment intervals are unclear, potentially leading
to detrimental practice variation: too frequent can result in overtreatment and greater strain on the healthcare
system; too infrequent could result in the neglect of high risk patients who require medication. This study aimed
to understand the different factors that general practitioners (GPs) consider when deciding on the reassessment
interval for patients previously assessed for primary CVD risk.
Methods: This paper combines quantitative and qualitative data regarding reassessment intervals from two
separate studies of CVD risk management. Experimental study: 144 Australian GPs viewed a random selection of
hypothetical cases via a paper-based questionnaire, in which blood pressure, cholesterol and 5-year absolute risk
(AR) were systematically varied to appear lower or higher. GPs were asked how they would manage each case,
including an open-ended response for when they would reassess the patient. Interview study: Semi-structured
interviews were conducted with a purposive sample of 25 Australian GPs, recruited separately from the GPs in the
experimental study. Transcribed audio-recordings were thematically coded, using the Framework Analysis method.
Results: Experiment: GPs stated that they would reassess the majority of patients across all absolute risk categories
in 6 months or less (low AR = 52 % [CI95% = 47–57 %], moderate AR = 82 % [CI95% = 76–86 %], high AR = 87 %
[CI95% = 82–90 %], total = 71 % [CI95% = 67–75 %]), with 48 % (CI95% = 43–53 %) of patients reassessed in under
3 months. The majority (75 % [CI95% = 70–79 %]) of patients with low-moderate AR (≤15 %) and an elevated risk
factor would be reassessed in under 6 months.
Interviews: GPs identified different functions for reassessment and risk factor monitoring, which affected recommended
intervals. These included perceived psychosocial benefits to patients, preparing the patient for medication, and
identifying barriers to lifestyle change and medication adherence. Reassessment and monitoring intervals were driven
by patient motivation to change lifestyle, patient demand, individual risk factors, and GP attitudes.
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Conclusions: There is substantial variation in reassessment intervals for patients with the same risk profile. This
suggests that GPs are not following reassessment recommendations in the Australian guidelines. The use of shorter
intervals for low-moderate AR contradicts research on optimal monitoring intervals, and may result in unnecessary
costs and over-treatment.
Keywords: Cardiovascular disease, Primary care, General practice, Prevention, Risk assessment
Background
International guidelines for cardiovascular disease (CVD)
prevention recommend the use of absolute risk (AR)
assessment to guide preventive medication, rather than
treating blood pressure and cholesterol as individual risk
factors [1–3]. Australian guidelines use age, sex, smoking,
diabetes, systolic blood pressure and cholesterol ratio to es-
timate the risk of a cardiovascular event in the next 5 years,
based on the Framingham model [1, 2, 4]. Preventive medi-
cation is recommended if AR is higher than 15 %, or 10–
15 % with other risk factors (e.g. significant family history
of CVD). Reassessment of AR is recommended after 2 years
for low risk patients (<10 %), 6–12 months for patients at
moderate risk (10–15 %), and according to clinical context
for high risk patients (>15 %). Patients on medication or
recommended to make lifestyle changes may be monitored
more frequently, but AR does not need to be reassessed.
These reassessment recommendations are based on
consensus-based expert clinical judgement and the
published literature [1, 2]. Other international guide-
lines use a 10 year timeframe, with varying medica-
tion thresholds and reassessment recommendations, if
reassessment is addressed at all [5–8].
Previous studies have shown that general practitioners
(GPs) do not consistently base their decisions regarding pri-
mary CVD prevention on AR [9–13]. The lack of uniformity
in guideline recommendations for reassessment intervals,
combined with the low utilisation of AR in practice is likely
to result in highly variable reassessment. This is a potential
concern, as reassessments that are too frequent can result in
overtreatment and greater strain on the healthcare system
[6, 14], while reassessments that are too infrequent could re-
sult in the neglect of high risk patients who require medica-
tion. This study aims to understand the different clinical and
psychosocial factors that GPs consider when recommending
the frequency of CVD risk reassessment and monitoring in
primary CVD prevention.
Methods
This study combines quantitative and qualitative data.
Questions on reassessment intervals were presented to
Australian GPs in two separate studies of CVD risk man-
agement [9, 12, 15, 16]. In this context, reassessment refers
to a patient returning to the GP for specific reassessment
of CVD risk, including re-measurement of blood pressure
and/or cholesterol. Primary assessment and management
results have been presented elsewhere [9, 12, 15, 16].
Ethical approval was obtained from the University of
Sydney Human Research Ethics Committee (11–2011/
14379) and the Sydney Local Health District Human
Research Ethics Committee (Protocol No X11-0200
and HREC/11/RPAH/294), and informed consent was
obtained from all participants.
Table 1 GP characteristics – study 1
Study 1 (n = 144)
Sex M 62 (43 %)
F 82 (57 %)
Age <40 18 (13 %)
40–49 33 (23 %)
50–59 61 (42 %)
60+ 30 (21 %)
Years of practice < 10 6 (7 %)
10–19 23 (16 %)
20–29 49 (34 %)
30+ 60 (42 %)
Number of GPs in
practice
1–5 72 (50 %)
6–10 44 (31 %)
11–15 18 (13 %)
16+ 6 (4 %)
Not applicable (Locum, etc.)
or no answer
4 (3 %)
Self-reported use of AR
(in practice)a
1 (Never) 18 (13 %)
2 27 (19 %)
3 39 (27 %)
4 38 (26 %)
5 (Always) 21 (14 %)
Self-reported use of AR
(in study cases)a
1 (Never) 12 (8 %)
2 15 (10 %)
3 37 (26 %)
4 45 (31 %)
5 (Always) 34 (24 %)
a1–5 Likert scale (1 = never, 5 = always); Percentages may not always add up to
100 due to missing responses
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Study 1
GPs currently practicing in Australia were recruited
between May and November 2012 at four GP conferences
(see Table 1).
In a paper-based questionnaire, respondents viewed a
generic patient scenario followed by a table with the
relevant values for AR, systolic blood pressure, total
cholesterol/HDL ratio, HDL, total cholesterol, age, gen-
der and smoking status. Four sets of cases were devel-
oped (see Table 2).
Each GP viewed 11 randomly selected cases, from a
pool of 43. GPs were asked: whether they would pre-
scribe cholesterol medication and/or blood pressure
medication (yes/no for each); when they would reassess
(open ended); and could comment on the case (open
ended). A more detailed explanation of the method and
cases is described elsewhere [12].
Statistical analysis
To analyse the GPs’ decisions regarding time to reassess-
ment according to risk profile, taking into account case
clustering per GP, we used logistic regressions, fitted
through generalised estimation equations (GEEs). The
GEEs will produce similar estimates to the conventional
logistic regression but the confidence intervals will be
more conservative because of the correlation between
observations due to clustering [17]. Time to reassessment
was dichotomised: <6 months and ≥6 months. 95 % CIs
for percentages were estimated from the GEEs, and statis-
tical analysis was conducted using SPSS V.21.
Study 2
Semi-structured interviews covering CVD risk assess-
ment and management were conducted with 25 GPs
between October 2011 and May 2012 [9] (see Table 3 for
participant characteristics). GPs were recruited via a letter
of invitation through their Divisions of General Practice.
Participants were asked to describe how they would man-
age three hypothetical cases (see Table 4), and were asked
specific questions about how they reassess primary CVD
risk (see Additional file 1). Interviews were conducted via
telephone (n = 23) or face to face (n = 2) by two public
health researchers (SM, CB), and were audio recorded
and transcribed verbatim. Interviews lasted between 22
and 55 min. A framework analysis method was used [18].
Three authors (SM, CB, JJ) developed the coding frame-
work by independently coding a subset of the data, and
discussing emerging themes to develop a preliminary
coding scheme, which was discussed and reviewed with
an experienced qualitative researcher (KM) to develop
the coding framework. SM and CB coded the remaining
transcripts, with new themes and revisions to the coding
framework discussed throughout the process. SM exam-
ined the final framework in order to identify overarching
themes and relationships, and results were discussed with
all authors, including two academic GPs (JD, PG).
Results
Study 1
Table 5 shows time to reassessment according to AR
categories. Across all risk categories, the majority of
Table 2 Patient case descriptions – study 1
Generic patienta scenario Description
A regular patient of yours presents for a “check-up” and has no current symptoms.
He/she has been trying to improve their diet and increase their physical activity levels.
You have several previous blood pressure readings at approximately the same level as
observed today. A recent test of electrolytes, liver function and renal function was normal.
• BMI: 27
• Past medical history: nil of note
• Family history: mother died of bowel cancer, nil family history of ischaemic heart disease
• Social history: married, lives at home
• Ethnicity: Caucasian
Patient case category Individual risk (IR) Absolute Risk (IR)
A (high IR, lower AR) High (either blood pressure or cholesterol) Lower (≤15 %)
Ai High (blood pressure only – systolic blood pressure [SBP] ≥147 mmHg Lower (≤15 %)
Aii High (cholesterol only – total cholesterol/HDL ratio [TC/HDL] ≥6.5 mmol/L Lower (≤15 %)
B (high IR, high AR) High (SBP ≥147 mmHg, TC/HDL ≥6.5 mmol/L) High (>15 %)
C (lower IR, high AR) Lower (SBP <147 mmHg, TC/HDL <6.5 mmol/L) High (>15 %)
D (lower IR, lower AR) Lower (SBP <147 mmHg,
TC/HDL <6.5 mmol/L)
Lower (≤15 %)
aApplies to all patient case categories
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patients (71 %, CI95% = 67–75 %) would be recalled for re-
assessment in under six months. The high and moderate
AR categories had similar reassessment intention within
6 months (87 %, CI95% = 82–90 % and 82 % CI95% = 76–
86 %, respectively), while only 52 % (CI95% = 47–57 %) of
the patients with low AR would be reassessed in this time
frame, as reported by the GPs. Overall, 48 % (CI95% = 43–
53 %) of patients would be recalled in under 3 months.
Many of the cases reassessed in under 6 months fall into
category A (high IR/lower AR – either SBP ≥147 mm Hg
or TC/HDL ≥6.5 mmol/L, AR ≤15 %). Seventy-five percent
(CI95% = 70–79 %) of patients in this category would be
reassessed in less than 6 months. The majority of these
cases fall into category Ai (high IR/lower AR – high blood
pressure only: SBP ≥147 mm Hg, AR ≤15 %), with 90 %
(CI95% = 85–94 %) of patients reassessed in less than 6
months, compared to 59 % (CI95% = 52–66 %) of patients in
category Aii (high IR/lower AR – high cholesterol only:
TC/HDL ≥6.5 mmol/L, AR ≤15 %). Table 6 shows time to
reassessment according to case category.
In open-ended comments, GPs often referred to re-
assessment and monitoring of lifestyle more generally,
particularly when preparing the patient for the possibility
of starting medication. This was common for category B
(high IR/high AR – SBP ≥147 mm Hg, TC/HDL ratio
≥6.5 mmol/L, AR >15 %) and category Ai (high IR/lower
AR – high blood pressure only: SBP ≥147 mm Hg, AR
≤15 %) cases where reassessment in less than 6 months
was recommended. Patients were also recalled for non-
CVD related matters, such as cancer screening, post-
menopausal health checks, and other blood tests to check
organ function and blood count.
There was some confusion about using AR-based
CVD prevention guidelines, and the concept of AR; sev-
eral comments asked “where does the risk come from?”
or asked why the patient’s AR was a particular level. This
type of comment was made for cases in category C
(lower IR/high AR – SBP <147 mm Hg, TC/HDL
<6.5 mmol/L, AR >15 %) which could reflect a lack of
understanding that the presence of multiple lower-level
individual risk factors can amount to high AR.
Study 2
Qualitative interviews provided insight into the range of re-
assessment times seen in the experimental study, with GPs
identifying various functions for reassessment and monitoring.
Table 7 provides a summary of reasons for shorter (<6months)
and longer (≥6 months) intervals. Although GPs were not spe-
cifically asked about monitoring function and intervals, these
emerged as key themes in the qualitative analysis. In this
context, monitoring refers to checks with the GP in regard
to CVD medication, individual CVD risk factors, lifestyle
changes, or other medical issues relevant for CVD (risk).
Reassessment and monitoring function
Psychosocial benefits
GPs made statements about the perceived psychosocial
benefits of monitoring for their patients, especially for
Table 4 Patient case descriptions – study 2
Case Sex Age Smoking status Y/N SBP (mmHg) TC (mmol/L) HDL (mmol/L) TC/HDL ARa (%) Study 1 equivalent case category
1 Male 61 N 156 4.9 1.6 3 9 Ai
2 Male 61 N 116 6.4 1 6.4 9 Aii
3 Male 61 Y 131 5.4 1.2 4.5 16 C
aAbsolute risk was not reported systematically to all GPs. GPs were informed of the patients’ AR if they asked for it, or if they had previously mentioned using
AR in their practice
Table 5 Time to reassessment according to the absolute CVD
Risk categories
Absolute risk category (% of cases)
N High (>15 %)
n = 519
Moderate
(10–15 %)
n = 430
Low (<10 %)
n = 635
Time to reassessment
Less than 1 month 261 27 16 11
1 to <3 months 451 35 37 22
3 to <6 months 346 25 28 19
6 to <12 months 247 9 15 24
12 to <24 months 148 4 3 19
24 or more months 32 0 1 5
Table 3 GP Characteristics – study 2
Study 2 (n = 25)
Sex M 10 (40 %)
F 15 (60 %)
Age < 40 6 (24 %)
40–49 8 (32 %)
50–59 7 (28 %)
60+ 4 (16 %)
Years of practice < 10 5 (20 %)
10–19 6 (24 %)
20–29 9 (36 %)
30+ 5 (20 %)
Number of GPs in practice 1–5 10 (40 %)
6–10 13 (52 %)
11–15 2 (8 %)
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lifestyle change and weight management. GPs saw fre-
quent monitoring as important for patient motivation,
engagement and reassurance.
“To keep them engaged…because if they are engaged
with you and want to work on it you can do lots of
things but if they disappear…you can’t do anything
until they come.” (ID5)
Reassessment of AR may play a part in this if the GP
feels it may aid patient management, or that a change in
AR will motivate the patient to continue with lifestyle
management.
“If you bring them back and you start saying ’ah
look your cholesterol has come down, look at your
risk, look on the CV calculator remember it was
there, look where it is now’…once you start seeing a
difference usually you’ll notice they get quite
excited.” (ID22)
Preparing the patient for medication
GPs saw reassessment of risk factors and regular monito-
ring of lifestyle changes as a method of getting patients
accustomed to the idea that they may need to start poten-
tially life-long medication.
“If they’re not fine then…also get them used to the
fact that they may well have to go onto medication
so when they do go onto medication whether that be
statins or whether it be anti-hypertensive, that they know
that....that they do require, this wasn’t a once off.” (ID7)
Table 6 Time to reassessment according to patient case categories
Patient case category (% of cases)
A Ai Aii B C D
High IRa lower ARb
(combined)
High IR lower AR
(BP onlyc)
High IR Lower AR
(chol. onlyd)
High IR High ARe Lower IR High AR Lower IR Lower AR
N = 788 N = 398 N = 390 N = 214 N = 277 N = 206
Time to reassessment
< 1 month 17 29 4 45 11 1
1 to <3 months 34 47 21 38 34 4
3 to <6 months 24 14 35 15 34 15
6 to <12 months 18 8 28 1 14 31
12 to <24 months 6 1 10 1 7 39
24 or more months 1 1 2 0 0 10
aHigh IR: elevated individual risk factor
blower AR: low or moderate absolute risk (≤15 %)
cBP only: systolic blood pressure ≥147 mmHg
dcholesterol only: total cholesterol/HDL ratio ≥6.5 mmol/L
eHigh AR: >15 %
Table 7 Summary of reasons given by GPs for reassessment and monitoring intervals
Shorter monitoring and/or reassessment period (<6 Longer monitoring and/or reassessment period (6+ months)
Patient drivers
• Low patient motivation to make lifestyle changes –
may need to start medication earlier.
• High patient motivation to make lifestyle changes –
maintain motivation with good results.
• Patient desires frequent monitoring and reassessment
Risk factor drivers
• Borderline for treatment with medication
• Monitoring of blood pressure and cholesterol after
lifestyle change prescription
• Comorbidities
• Weight monitoring
• Smokers: frequent monitoring of other risk factors and
opportunities to reassess willingness to quit.
GP drivers
• Strong focus on prevention/screening
• Strong focus on reducing risk through lifestyle change
rather than medication
• View that you can monitor more often than recommended
by guidelines without over-servicing
Patient drivers
• High patient motivation - patient is motivated by early success
with lifestyle change and can manage alone for longer intervals.
• Longer time period needed for lifestyle changes to show results,
in order not to discourage or demotivate patient with lack of success.
Risk factor drivers
• Risk factors have decreased or are well controlled with medication
• No urgent CVD risk factors that need to be addressed,
and/or absolute risk is low
GP drivers
• Too busy to reassess CVD risk unless requested by patient
• Use of opportunistic monitoring and reassessment
• Follow guideline recommendations on reassessment and monitoring
frequency for low/moderate risk patients
• Concern about over-servicing asymptomatic patients
• Involvement of other practitioners in patient’s care
(dietician, exercise physiologist, etc.)
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This approach may also involve reassessment of AR as
a way of showing patients an objective measure of why
they need to start medication.
“I do find it useful to do the calculation again…for the
patient so they can see there is some sort of objective
reason why a medication would now be beneficial.
They’ve…tried certain lifestyle changes in the
community…and if they still haven’t reached target…
it seems very reasonable then and to set some
pharmacotherapy for that to be done.” (ID16)
Identification of barriers
Another function of monitoring mentioned by GPs is to
provide an opportunity to discuss barriers to adherence,
for both lifestyle change and medication.
“For those that aren’t getting there you may need to
explore further…so you need to sort of be constructive
and go back to if you haven’t lost weight well it’s not
just come back in a month its well what are the
barriers that are preventing this and how can we
overcome those barriers.” (ID31)
Reassessment and monitoring intervals
Patient drivers: motivation to make lifestyle changes
Patient motivation also impacted monitoring and reassess-
ment intervals, with frequent monitoring seen to be dis-
couraging if the patient does not see the results of their
efforts.
“There is a fine line between doing it too early and
them not seeing any results or…doing it…so they can
see something happening.” (ID11)
GPs cited both high and low patient motivation to
change lifestyle as a reason to monitor frequently: for high
motivation patients because it helps maintain motivation,
and low motivation patients because they will need to
commence medication sooner.
High motivation: “if they....looked as though they were
listening and trying to think ok I am going to modify
my diet and lifestyle. I would say look lets test it in
2 months and see what change it makes and see if
that is significant for you.” (ID29)
Low motivation: “the ones who really haven’t done
anything, still putting on weight and smoking, I do
try to see them more often.” (ID9)
However, GPs also cited high and low patient moti-
vation as a reason for longer monitoring and reassessment
intervals: highly motivated patients may be monitored less
frequently once they start achieving lifestyle change goals,
while frequent monitoring of patients unwilling to make
lifestyle changes or take medication may be seen as
inappropriate and futile.
High motivation: “Well I suppose if you see them 3
monthly first of all and they’ve done really well and
they have dropped the weight and they’re exercising
and they’re feeling really motivated then there is no
point in checking their cholesterol again every
3 months.” (ID9)
Low motivation: “He is new to me today this guy and
he has come in with cholesterol results basically every
3 months, they’ve been doing them for the last 2 years
and I go what for, he has not changed over that time,
he is not prepared to change and he is not going to
take a statin and I go well what’s the point of doing
it every 3 months, so we can have the same
conversation.“(ID11)
Patient drivers: demand for reassessment
Other patient driven factors mentioned by GPs that are
not related to lifestyle change motivation include patient
desire for regular blood tests, whether the GP thinks it is
required or not:
“I get patients who are very keen to do blood tests.
Everybody seems very keen to know their cholesterol
and their sugars and things…I sometimes have a
battle with some patients because they want to do it
(cholesterol testing) every 6 months, once a year is
enough.” (ID10)
Several GPs also mentioned gender as an element that
influences monitoring and reassessment frequency, with
men failing to present according to the schedule set by
the GP.
“If they are women they are going to come back, if they
are men you to have to sort of chase them.” (ID5)
Risk factor drivers
The presence of certain risk factors drove some GPs to
recall patients more frequently, including comorbidities,
and factors that are not taken into account in the AR
calculation, such as weight and family history. Smokers
who are not attempting to quit may also be encouraged
by their GP to visit more frequently to monitor their
other risk factors.
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“If you’ve got some severely obese kind of young guy
with a massive family history you would be more
concerned about him and more likely to chase him up
than someone who is relatively fit and healthy and
has the same absolute score.” (ID9)
GP drivers
GPs’ own attitudes regarding prevention and guidelines
influenced the frequency of monitoring, ranging from a
strong focus on screening all patients, to concern about
over-servicing.
“I am measuring all those factors at least every
12 months on virtually all my patients…or maybe
6 months…that’s the way I run my practice, I do a
lot of screening.” (ID26)
“I try to get them back at the 6 weeks, month, 6 weeks
- 3 months, I know it’s always sooner than what the
GP guidelines are but I like to keep it a little bit on the
front burner while not massively over-servicing” (ID2)
Some GPs were concerned about over-servicing
asymptomatic patients. GPs mentioned that the con-
sultation should be valuable to the patient, rather than
an inconvenience.
“I always feel really…hesitant about getting well
people to come in and we don’t bulk bill, so getting
them to come in and pay for a check which you
know kind of says they’re ok.” (ID29)
“I don’t want the practice consultation to be viewed
as a chore but really something....that they get
meaning and get use out of it” (ID16)
GP attitudes regarding lifestyle change also affected mo-
nitoring and reassessment intervals. Several GPs thought
that more frequent monitoring should be encouraged for
patients attempting lifestyle change.
“If somebody has got a weight problem, obesity, then
I will ask them to see me in a couple of weeks so I can
check their weight and that motivates them. Because
if they know they’re going to the Doctor and he’s going
to check their weight they’re more conscious about
weight…I won’t ask them to come and see me in
say 3 or 6 months, they won’t come, we will
lose them.” (ID38)
Discussion
The results of both studies show a substantial range in
reassessment intervals for patients in the same CVD risk
categories, with the interview study also revealing a wide
range in GPs’ reasoning behind reassessment and moni-
toring intervals that is sometimes contradictory.
The experimental study results showed that across all
risk categories, the majority of patients would be recalled
for reassessment in under 6 months, and almost half in
under 3 months. While high risk patients were reassessed
in accordance with Australian guidelines, low-moderate
risk patients were reassessed earlier [1, 2]. Perhaps of most
concern is the finding that 95 % of low risk patients (AR
<10 %) would be reassessed earlier that the Australian
guidelines recommend [1, 2]; and 52 % of those would
be reassessed within 6 months. In contrast, recent model-
ling research has found that reassessment of primary
CVD risk before 8–10 years is not warranted for most
people who do not require preventive medication at
baseline [6].
The difference in reassessment times between category
Ai cases (high IR/lower AR – high blood pressure only:
SBP ≥ 147 mm Hg, AR ≤15 %) and category Aii cases (high
IR/lower AR – cholesterol only: TC/HDL ≥ 6.5 mmol/L,
AR ≤15 %) is consistent with previously reported results
from this study which found that GPs’ decision-making
was more influenced by individual risk factors than AR,
especially for blood pressure lowering medication. Blood
pressure lowering medication was prescribed in 83 % of
the category Ai cases (high IR/lower AR – high blood
pressure only: SBP ≥147 mm Hg, AR ≤15 %), compared
with cholesterol lowering medication being prescribed in
34 % of the category Aii cases (high IR/lower AR – choles-
terol only: TC/HDL] ≥6.5 mmol/L, AR ≤15 %) [12]. This
pattern is confirmed in the reassessment intervals for these
categories, with 90 % of high SBP/lower AR cases being
reassessed in less than 6 months, compared to 59 % of high
cholesterol/lower AR cases.
The broad range of reassessment times given by diffe-
rent GPs for the same cases is also suggestive of a gen-
eral lack of awareness of the primary CVD prevention
guidelines, in particular the use of AR. For example, one
case in category Ai (high IR/lower AR – high blood
pressure only: SBP ≥147 mm Hg, AR ≤15 %) had a range
of reassessment responses from 2 to 3 days up to 5 years,
with similar ranges in other categories. Previous research
has also pointed to an evidence-practice gap in the uptake
of AR assessment as a tool for primary CVD prevention,
but reassessment has not specifically been investigated in
this literature [19–21]. Although in this hypothetical
study high risk patients would be recalled for CVD risk
reassessment sooner, previous studies have shown that in
practice many people who fall into this category are
undertreated [20, 21].
However, the qualitative results reveal justifications for
frequent monitoring and reassessment of CVD risk that
are not necessarily accounted for in the guidelines,
McKinn et al. BMC Family Practice  (2016) 17:107 Page 7 of 9
including the perceived benefits of more frequent moni-
toring and reassessment on patient motivation to make
and maintain lifestyle changes. Perceived patient motiv-
ation can be used as a rationale for both frequent and in-
frequent reassessment intervals. Additionally, several GPs
mentioned the difficulty of convincing lower risk patients
that they do not require frequent blood tests and reassess-
ment. In the experimental study, GPs also made com-
ments about recalling patients for non-CVD related
matters even though the question was posed in the con-
text of CVD risk assessment. This may reflect how GPs
view CVD risk in the context of their patient’s overall
health and the broad spectrum of risk factors that GPs are
continuously monitoring and (re)assessing in their pa-
tients. These varied reasons for monitoring and reassess-
ment, which take into account both biological and
psychosocial patient factors, are not acknowledged in the
guidelines and lead to wide practice variability. More guid-
ance is needed for GPs around when to perform CVD risk
reassessment to inform decision-making versus monitor-
ing risk factors in order to fulfil other psychosocial func-
tions. It should be noted that while the experiment
presented here deliberately removed contextual patient
factors such as preferences and other health concerns,
these are important considerations for patient-centred
practice.
The strengths of this study include 1) a heterogeneous
sample and 2) the use of both quantitative and qualitative
methods in order to enhance understanding of GPs’
decision-making regarding reassessment of primary CVD
risk. The main limitations are that 1) GPs who parti-
cipated in the study may be more or less supportive of
using AR assessment than GPs in the wider community,
2) the study relied on self-reported behaviour, which may
differ from actual practice, and 3) GPs in the experimental
study were asked “When would you reassess this patient?”,
so it is possible that for patients who were prescribed
a blood pressure or cholesterol lowering medication,
GPs answered this question in terms of treatment moni-
toring, rather than CVD risk reassessment. However, this
does not change the key finding that the majority of low
risk patients, who should not be prescribed medication
according to the guidelines [1], were reassessed much
earlier than recent modelling recommends: less than 1 year
compared to 8–10 years [6].
Conclusions
There is a lack of evidence-based guidance for reassessing
primary CVD risk, and as these studies show, what GPs do
in practice is very inconsistent. Many are recalling patients
too frequently, but the reasons reflect a broader view of
patients’ health, incorporating psychosocial factors. The use
of shorter intervals for low-moderate AR contradicts re-
search on optimal monitoring intervals [6], and may result
in unnecessary costs and over-treatment. Evidence on when
to reassess patients’ primary CVD risk needs to be better
integrated into clinical practice guidelines, while also ac-
knowledging other legitimate reasons for more frequent
monitoring.
Additional file
Additional file 1: Study 2 qualitative interview questions about how
GPs reassess primary CVD risk. (DOCX 14 kb)
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